← Leaderboards
Christopher R McCurdy
University Of Florida
$12,051,179
Attributed
$17,855,599
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2006–23$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$17,855,599 · 11
By mechanism
R01$6,763,538 · 3
UH3$4,479,677 · 1
UG3$3,574,538 · 1
P20$2,897,173 · 5
R03$140,673 · 1
Top collaborators
- Lance R Mcmahon14 shared
Most similar at University Of Florida
Same institution · by research overlap
- Lance R McMahon$14,694,531
- Abhisheak Sharma$212,097
- Julie A Marusich$2,280,423
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoReceptorPharmaceutical PreparationsIn VitroOpioid ReceptorRattusBrainOpioidAgonistLigandsMitragynaDrug KineticsOpioid AbusePharmacologyPlasmaDesignDoseBiological AvailabilityPharmacophoreLigand BindingAlkaloidsBehavioralDrug DiscriminationAffinity
Grant awards (29)
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2023 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$705,717
R01 · FY2023 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$72,690
R01 · FY2023 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2022 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$693,433
R01 · FY2022 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$72,817
UH3 · FY2022 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$72,690
R01 · FY2022 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2021 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$681,503
R01 · FY2021 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$72,817
UH3 · FY2021 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$1,551,049
UG3 · FY2020 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$669,920
R01 · FY2020 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$2,023,489
UG3 · FY2019 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$658,673
R01 · FY2019 · DA
Optimization of non-peptide probes for the NPFF receptor system$489,241
R01 · FY2016 · DA · contact PI
Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)$2,045,714
P20 · FY2015 · GM · contact PI
Optimization of non-peptide probes for the NPFF receptor system$485,817
R01 · FY2015 · DA · contact PI
Optimization of non-peptide probes for the NPFF receptor system$498,705
R01 · FY2014 · DA · contact PI
Novel Pharmacologic Interventions for Drugs of Abuse$335,217
R01 · FY2011 · DA · contact PI
Novel Pharmacologic Interventions for Drugs of Abuse$345,584
R01 · FY2010 · DA · contact PI
Novel Pharmacologic Interventions for Drugs of Abuse$349,075
R01 · FY2009 · DA · contact PI
MISSISSIPPI COBRE: PROJ 1: MITRAGYNINE BASED OPIOID LIGANDS$196,924
P20 · FY2009 · RR · contact PI
Novel Pharmacologic Interventions for Drugs of Abuse$349,075
R01 · FY2008 · DA · contact PI
MISSISSIPPI COBRE: PROJ 1: MITRAGYNINE BASED OPIOID LIGANDS$196,764
P20 · FY2008 · RR · contact PI
Novel Pharmacologic Interventions for Drugs of Abuse$356,198
R01 · FY2007 · DA · contact PI
MISSISSIPPI COBRE: PROJ 1: MITRAGYNINE BASED OPTOID LIGANDS$200,851
P20 · FY2007 · RR · contact PI
MISSISSIPPI COBRE: PROJ 1: MITRAGYNINE BASED OPTOID LIGANDS$256,920
P20 · FY2006 · RR · contact PI
Salvinorin A: A Structurally Novel Opioid Agonist Lead$68,923
R03 · FY2004 · DA
Salvinorin A: A Structurally Novel Opioid Agonist Lead$71,750
R03 · FY2003 · DA